Mitoxantrone
- Generic Name
- Mitoxantrone
- Drug Type
- Small Molecule
- Chemical Formula
- C22H28N4O6
- CAS Number
- 65271-80-9
- Unique Ingredient Identifier
- BZ114NVM5P
Overview
An anthracenedione-derived antineoplastic agent.
Background
An anthracenedione-derived antineoplastic agent.
Indication
For the treatment of secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis
Associated Conditions
- Acute Lymphoblastic Leukemia (ALL)
- Acute Myeloid Leukemia
- Acute Promyelocytic Leukemia
- Hodgkin's Lymphoma
- Metastatic Breast Cancer
- Non-Hodgkin's Lymphoma (NHL)
- Progressive Relapsing Multiple Sclerosis
- Relapsed Leukemia
- Relapsed Lymphomas
- Relapsing Remitting Multiple Sclerosis (RRMS)
- Secondary Progressive Multiple Sclerosis (SPMS)
- Hormone refractory, advanced Prostate cancer
- Relapsed Hepatocellular carcinoma
Clinical Trials
FDA Approved Products
Mitoxantrone
Manufacturer:Hospira, Inc.
Route:INTRAVENOUS
Strength:2 mg in 1 mL
Approved: 2022/04/15
NDC:61703-343
Singapore Approved Products
MITOXANTRONE BAXTER INJECTION 2 mg/ml
Manufacturer:BAXTER ONCOLOGY GMBH
Form:INJECTION
Strength:2 mg/ml
Online:Yes
Approved: 2001/08/15
Approval:SIN11629P
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.
© Copyright 2025. All Rights Reserved by MedPath